Key Highlights
- Sun Pharmaceutical Industries has put forth a binding all-cash proposal valued at $12 billion to purchase Organon (OGN)
- Shares of OGN skyrocketed 41% to reach $8.25 during Friday trading, following an 18% climb to $6.91 the previous day
- The Indian drugmaker has wrapped up more than three months of comprehensive due diligence and is securing financing through JPMorgan and MUFG
- The transaction, if finalized, would represent the biggest international M&A deal ever executed by an Indian pharmaceutical firm
- Shares of Sun Pharmaceutical declined 3% on the Mumbai exchange after the acquisition news broke
Organon’s shares have experienced an extraordinary two-day rally. The women’s healthcare specialist headquartered in New Jersey saw its stock price leap 41% during Friday’s morning session to $8.25, building on the previous day’s 18% increase, after news surfaced that Sun Pharmaceutical Industries had presented a formal $12 billion acquisition proposal.
The disclosure originated from India’s Economic Times, which indicated that the Mumbai-headquartered pharmaceutical manufacturer had progressed past the exploratory phase and delivered a binding, all-cash proposal. Sun Pharma’s pursuit of this transaction has spanned over three months.
Organon’s present market capitalization stands at approximately $1.8 billion, which means the $12 billion proposal represents a significant premium above its existing market value.
The funding structure for this acquisition is being arranged with assistance from prominent financial institutions. JPMorgan and Japan’s MUFG are among the international banking giants facilitating Sun Pharma’s financing strategy.
Organon’s Corporate History
Organon emerged as an independent entity following its separation from Merck in 2021. The company specializes in reproductive medicine, birth control, and fertility treatments, while maintaining additional product lines in dermatology, neurology, and cardiovascular therapies.
The organization has navigated through challenging times recently. In October 2025, Chief Executive Kevin Ali resigned following an internal board inquiry that uncovered what the company characterized as inappropriate sales tactics employed to artificially boost quarterly performance.
This isn’t Sun Pharma’s initial approach toward Organon. In January, the Economic Times disclosed that Sun Pharma had submitted a preliminary, all-cash proposal and was gearing up to commence due diligence. Friday’s development signals substantial advancement beyond that initial phase.
Implications for Sun Pharma
If this transaction reaches completion, it would establish a new benchmark as the largest international acquisition in the history of Indian pharmaceutical companies — setting an industry milestone.
Sun Pharmaceutical’s stock experienced negative movement following the announcement, sliding 3% on the Mumbai stock exchange Friday. Such market reactions are typical when acquiring companies announce substantial, leverage-dependent transactions.
Both Organon and Sun Pharmaceutical declined to provide statements to media outlets at the time of publication.
OGN shares had been languishing at suppressed price levels prior to this week’s dramatic upswing. The consecutive gains of 18% and 41% mark a remarkable reversal in market perception surrounding the company’s stock.
As of Friday’s trading session, Sun Pharma is reportedly in the concluding phases of its acquisition bid, with financial backing being finalized concurrent with the binding proposal.
